FDA Approves New COPD Maintenance Treatment
DUAKLIR PRESSAIR (aclidinium bromide and formoterol fumarate) provides LAMA/LABA therapy. (Source: ConsultantLive)
Source: ConsultantLive - April 24, 2019 Category: Internal Medicine Authors: David Frabotta Source Type: news
Duaklir Pressair (Aclidinium Bromide and Formoterol Fumarate Inhalation Powder) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 4, 2019 Category: Drugs & Pharmacology Source Type: news
Duaklir Pressair (Aclidinium Bromide and Formoterol Fumarate Inhalation Powder) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 3, 2019 Category: Drugs & Pharmacology Source Type: news
FDA OKs Duaklir Fixed-Dose Combination Inhaler for COPD FDA OKs Duaklir Fixed-Dose Combination Inhaler for COPD
Duaklir combines aclidinium bromide and formoterol fumarate and is administered twice daily via a breath-actuated inhaler for maintenance treatment of COPD.FDA Approvals (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - April 1, 2019 Category: Primary Care Tags: Pulmonary Medicine News Alert Source Type: news
FDA Approves Duaklir Pressair (aclidinium bromide and formoterol fumarate) for Maintenance Treatment of Chronic Obstructive Pulmonary Disease
Oxford, UK– 1 April 2019: Circassia Pharmaceuticals plc (“Circassia” or“the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Drug Administration... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 1, 2019 Category: Drugs & Pharmacology Source Type: news
Tudorza Pressair (Aclidinium Bromide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 27, 2018 Category: Drugs & Pharmacology Source Type: news
Aclidinium bromide/formoterol in COPD: Added benefit for certain patient groups
Patients with COPD grade III with no more than one flare-up per year and grade II patients benefit from the new aclidinium Bromide/formoterol drug combination, researchers note. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 12, 2015 Category: Science Source Type: news
Federal Register: Determination of Regulatory Review Period for Purposes of Patent Extension; TUDORZA PRESSAIR
The FDA has determined the regulatory review period for TUDORZA PRESSAIR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent... (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - May 4, 2015 Category: Medical Equipment Source Type: news
Duaklir Genuair for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Duaklir Genuair (aclidinium bromide / formoterol fumarate) is an inhalation powder indicated as a maintenance bronchodilator treatment for chronic obstructive pulmonary disease (COPD). (Source: Drug Development Technology)
Source: Drug Development Technology - December 10, 2014 Category: Pharmaceuticals Source Type: news
AstraZeneca obtains European approval for Duaklir Genuair to treat COPD
British-Swedish drugmaker AstraZeneca has received marketing approval from the European Commission (EC) for Duaklir Genuair (aclidinium bromide/formoterol fumarate 340/12mcg). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 24, 2014 Category: Pharmaceuticals Source Type: news
Benefits of Aclidinium Persist to 1 Year for COPDBenefits of Aclidinium Persist to 1 Year for COPD
The long-acting muscarinic receptor antagonist aclidinium bromide continued to be effective for up to 52 weeks, according to the ACCORD COPD II extension study. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 3, 2014 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
EC's CHMP Recommends Combo Inhalers for COPD, AsthmaEC's CHMP Recommends Combo Inhalers for COPD, Asthma
The committee has endorsed the combination of aclidinium bromide/formoterol fumarate for COPD, and a budesonide/formoterol combination for COPD and asthma. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 26, 2014 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news
Bronchodilator Combo Works Best for COPD
CHICAGO (MedPage Today) -- Combining formoterol (Foradil Aerolizer) and aclidinium (Tudorza Pressair) in a single twice-daily inhaler was better than either drug alone in chronic obstructive pulmonary disease, a randomized trial showed. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - October 31, 2013 Category: Journals (General) Source Type: news
Added benefit of aclidinium bromide is not proven
(Institute for Quality and Efficiency in Health Care) In an early benefit assessment IQWiG examined whether aclidinium bromide alleviates symptoms of chronic-obstructive pulmonary disease better than conventional drugs. However, such an added benefit cannot be inferred from the drug manufacturer's dossier as it does not provide robust results. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 30, 2013 Category: Global & Universal Source Type: news
Aclidinium Bromide, New Anticholinergic, for Managing COPDAclidinium Bromide, New Anticholinergic, for Managing COPD
Learn more about a new key player in COPD management. Therapeutic Advances in Respiratory Disease (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 14, 2013 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news
